Small Airway Disease in Pulmonary Hypertension-Additional Diagnostic Value of Multiple Breath Washout and Impulse Oscillometry
- PMID: 30544842
- PMCID: PMC6306708
- DOI: 10.3390/jcm7120532
Small Airway Disease in Pulmonary Hypertension-Additional Diagnostic Value of Multiple Breath Washout and Impulse Oscillometry
Abstract
Airways obstruction is frequent in patients with pulmonary hypertension (PH). Small airway disease (SAD) was identified as a major contributor to resistance and symptoms. However, it is easily missed using current diagnostic approaches. We aimed to evaluate more elaborate diagnostic tests such as impulse oscillometry (IOS) and SF₆-multiple-breath-washout (MBW) for the assessment of SAD in PH. Twenty-five PH patients undergoing body-plethysmography, IOS and MBW testing were prospectively included and equally matched to pulmonary healthy and non-healthy controls. Lung clearance index (LCI) and acinar ventilation heterogeneity (Sacin) differed significantly between PH, healthy and non-healthy controls. Likewise, differences were found for all IOS parameters between PH and healthy, but not non-healthy controls. Transfer factor corrected for ventilated alveolar volume (TLCO/VA), frequency dependency of resistance (D5-20), resonance frequency (Fres) and Sacin allowed complete differentiation between PH and healthy controls (AUC (area under the curve) = 1.0). Likewise, PH patients were separated from non-healthy controls (AUC 0.762) by D5-20, LCI and conductive ventilation heterogeneity (Scond). Maximal expiratory flow (MEF) values were not associated with additional diagnostic values. MBW and IOS are feasible in PH patients both providing additional information. This can be used to discriminate PH from healthy and non-healthy controls. Therefore, further research targeting SAD in PH and evaluation of therapeutic implications is justified.
Keywords: impulse oscillometry; lung clearance index; multiple breath washout; pulmonary hypertension; small airway disease.
Conflict of interest statement
The authors declare no conflict of interest directly related to the content of the manuscript. The following financial activities outside the submitted work exist: F. Trinkmann received travel support from Actelion, Boehringer Ingelheim, Chiesi, Novartis, Mundipharma and TEVA as well as speaker / consultation fees from Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, GlaxoSmithKline, Roche and Novartis. J. Saur received travel support and speaker fees from Boehringer Ingelheim, GlaxoSmithKline, GSK, Novartis und Roche. M. Borggrefe received speaker / consultation fees from Bayer, Boehringer Ingelheim, Daiichi Sankyo, Impulse Dynamics and Zoll Medical. I. Akin received travel support as well as speaker / consultation fees Abiomed, Bayer, Boehringer Ingelheim und St. Jude Medical.
Figures
References
-
- Galie N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur. Respir. J. 2015;46:903–975. doi: 10.1183/13993003.01032-2015. - DOI - PubMed
-
- Voelkel N.F., Quaife R.A., Leinwand L.A., Barst R.J., McGoon M.D., Meldrum D.R., Dupuis J., Long C.S., Rubin L.J., Smart F.W., et al. Right ventricular function and failure: Report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114:1883–1891. doi: 10.1161/CIRCULATIONAHA.106.632208. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
